Significant Shareholder Notification from Morgan Stanley
Bavarian Nordic A/S has made an important announcement regarding its shareholder structure. Recently, they received notification from Morgan Stanley, indicating that the investment firm holds 4.92% of the total shares and voting rights in Bavarian Nordic as of a recent date.
About Bavarian Nordic
Bavarian Nordic is a prominent global vaccine company dedicated to improving health and saving lives through the development of innovative vaccines. The company is recognized as a critical supplier of mpox and smallpox vaccines to governments, demonstrating its commitment to public health preparedness. The portfolio of Bavarian Nordic also includes an advanced array of travel vaccines, catering to a diverse consumer base.
Mission and Values
The mission of Bavarian Nordic is clear: to enhance global health outcomes through innovative vaccine solutions. Each product is developed with the intent to address unmet medical needs and support health authorities in protecting populations against infectious diseases. The company's focus on research and development propels its mission forward, as it seeks to create vaccines that are both effective and accessible.
Engagement with Investors
As part of its transparent communication strategy, Bavarian Nordic encourages engagement with investors. The company provides avenues for contact through dedicated investor relations personnel, ensuring that inquiries are addressed and information is readily available. Investors who wish to connect can reach out directly to Disa Tuominen, the Investor Relations Manager in Europe, or Graham Morrell from the Gilmartin Group for inquiries specific to the United States.
Investor Relations Contacts
Contacting investor relations provides a valuable opportunity for stakeholders to gain insights into the company's strategic direction and operational performance. Disa Tuominen is available for questions in Europe, while Graham Morrell offers support for inquiries in the United States, showcasing the company's commitment to maintaining open lines of communication.
Company Communication
In addition to investor relations, Bavarian Nordic emphasizes the importance of media communication. Nicole Seroff, serving as Vice President of Corporate Communications, is the point of contact for any media-related inquiries. This highlights Bavarian Nordic's commitment to transparency and ensures that accurate information reaches the public and stakeholders alike.
Company Announcement No. 39
In the latest company announcement dated 39/2025, Bavarian Nordic reaffirms its dedication to shareholder engagement and updates. It clearly establishes the structure of communication and the responsibilities of key personnel within the company to foster trust and facilitate information sharing.
Frequently Asked Questions
What percentage of shares does Morgan Stanley hold in Bavarian Nordic?
Morgan Stanley holds 4.92% of the shares and voting rights in Bavarian Nordic A/S.
What is the mission of Bavarian Nordic?
Bavarian Nordic is committed to improving health and saving lives through the development of innovative vaccines.
Who can investors contact for inquiries?
Investors can contact Disa Tuominen in Europe or Graham Morrell in the U.S. for any inquiries related to the company.
What vaccines does Bavarian Nordic specialize in?
Bavarian Nordic specializes in mpox, smallpox, and travel vaccines, among other innovative vaccine solutions.
How can one get company updates?
Company updates are communicated through official announcements, and stakeholders can also reach out to investor relations for specific information.
